Topic

Mike Hennessy Jr. is the President and CEO of 

Articles

How the Republican and Democrat presidential candidates might appeal to voters on this topic is starting to be seen. 

Drug Prices on Debate

Cheryl Barton is director of PharmaVision, 

Innovative solutions are making personalized cell and gene therapies accessible to all.

Frontrunners in Automated Cell and Gene Therapy Manufacturing

Emerging therapies, such as cell and gene therapies, come with unique challenges that must be planned for in advance.

The Logistics of Developing an Emerging Therapy

Feliza Mirasol is the science editor for 

Lilly has increased its manufacturing investment for biologics in Limerick, Ireland, by $1 billion while launching its new $800 million facility in Kinsale.

Lilly Plans to Grow its Biologics Manufacturing Footprint in Ireland with $1.8 Billion Expansion

The finalists for the 2024 CPHI Pharma Awards are spread across 14 categories, which include future leaders, women of the year, and an “at the heart of pharma” category.

CPHI Pharma Award Finalists Announced for 2024

With the completion of its acquisition of Morphic, Lilly expands its immunology pipeline to include Morphic's oral integrin therapies to address inflammatory bowel disease.

Lilly Completes $3.2 Billion Acquisition of Morphic, Boosting Its IBD Pipeline

Under a deal worth potentially up to $1.3 billion, Merck, known as MSD outside of the United States and Canada, will acquire CN201, a next-generation bispecific antibody, from Curon Biopharmaceutical. 

Merck Plans to Acquire Investigational Bispecific Antibody from Curon Biopharmaceutical in $1.3 Billion Deal

Genentech will leverage Sangamo’s proprietary capsid delivery platform and epigenetic regulation capabilities to develop genomic medicines to address certain neurodegenerative diseases.

Genentech Licenses Sangamo Therapeutics’ Epigenetic Regulation and Capsid Technologies in Nearly $2 Billion Deal for Genomics Medicines

Under the license agreement, Andelyin Biosciences will expand its AAV Curator Platform by including MyoAAV plasmids developed by Broad Institute of MIT and Harvard.

Andelyn Biosciences Inks License Agreement with Broad Institute of MIT to Expand AAV Platform Offering

With a $15 million fund-raising goal, US Specialty Formulations plans to invest in expanding its biopharma facility in Allentown, Pa.

BioBusiness